1.800.KIDS DOC | 1.800.543.7362
Lurie Children's Specialties & ConditionsEpilepsy Program Research - Clinical Trials

Pediatric Epilepsy Research

Here at Lurie Children’s, our research team works tirelessly to bring our patients and families an abundance of clinical research opportunities, in a mission to discover new cures, every day. Our multidisciplinary team of physician-scientists conduct various research projects to help promote patient care and better educate families. We participate in studies funded by the National Institute of Health (NIH), pharmaceutical companies and our own investigator-initiated studies. We hope our research efforts will improve treatment for children with epilepsy.

Our current focus is in precision medicine, which strives to determine optimal personalized treatment methods based on genetic testing results. We hope to achieve the same success as with our existing studies, which will help our patients tremendously.

 

Learn more about Epilepsy Precision Medicine - Research Studies

Current Epilepsy Center Clinical Trials

EEG Biomarkers of Disease Progression in Lennox-Gastaut Syndrome

  • IRB #: 2018-2054
  • Study Contact: Marija Stosic, mstosic@luriechildrens.org
  • PI: Dr. Sunita Misra 
  • Description: This study is an assessment of electroencephalograms of children with Lennox-Gastaut Syndrome, treated at Lurie Children's. The goal of this study is to identify patterns in the EEG that could lead to earlier diagnoses in the future.


GWEP 1415- An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes

GWEP 1521- A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately-controlled focal seizures.

A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabtrin Induction Therapy (I-SITT)

  • IRB #: 2017-1371 
  • Study Contact: Stefanie McCormack, smccormack@luriechildrens.org
  • PI: John Millichap
  • Description: The purpose of this study is to learn more about the best way to treat children with West syndrome. This study seeks to understand Cosyntropin, a new form of a commonly used drug to treat infantile spasms. Cosyntropin will be compared with vigabatrin, another commonly used drug to treat infantile spasms. We hope to understand if Cosyntropin alone or used in combination with vigabatrin works better than just vigabatrin alone. 


An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies

Predictive Mechanisms and Clinical Biomarkers of SUDEP

  • IRB #: 2013-15341
  • Study Contact: Marija Stosic, mstosic@luriechildrens.org
  • PI: Dr. John Millichap
  • Description: Center for SUDEP Research (CSR) is the second Center Without Walls for collaborative research in the Epilepsies. This milestone-driven collaboration brings together extensive and diverse expertise to tackle SUDEP and will identify patients who are at higher risk of SUDEP, enabling further appropriate intervention and prevention of SUDEP in that specific population.


Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome



A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥2 Years Old and Young Adults With Dravet Syndrome